TARGET AUDIENCE
This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of hematologic cancers.

OVERVIEW OF ACTIVITY
Hematologic cancers include the lymphomas, the leukemias, multiple myeloma (MM) and other disorders stemming from lymphoid and myeloid progenitor cell lines. It is estimated that approximately 176,200 new lymphoid, myeloid and leukemic cancer cases will be diagnosed in the United States in the year 2019, and 56,770 individuals will die from these diseases. Currently more than 70 drug products are labeled for use in the management of hematologic cancers, with more than 120 distinct FDA-approved indications. Although this extensive list of available treatment options is reassuring for patients and oncology healthcare professionals, it poses a challenge to the practicing clinician who must maintain up-to-date knowledge of their appropriate application across a vast spectrum of tumor types. This is particularly true within the realm of Hodgkin and non-Hodgkin lymphomas, including chronic lymphocytic leukemia (CLL), which in the past several years has yielded a staggering number of important clinical and research advances.

These 2 postmeeting interviews with faculty from a satellite symposium held during the 2019 ASCO Annual Meeting explore the most significant therapeutic advances of the past year by using the perspectives of leading hematologic oncology experts to gain a better understanding of new management strategies and lingering clinical controversies in the management of Hodgkin and non-Hodgkin lymphomas, including CLL, and MM. This activity will assist medical oncologists, hematologists and other allied healthcare professionals in finding answers to the individualized questions and concerns they frequently encounter and to in turn provide high-quality cancer care.

LEARNING OBJECTIVES

• Evaluate existing and emerging clinical research data to formulate therapeutic recommendations for patients with newly diagnosed and relapsed/refractory (R/R) diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma and Hodgkin lymphoma (HL).
• Individualize the selection and sequence of systemic therapies for patients with newly diagnosed and R/R CLL, considering clinical presentation, biomarker profile and psychosocial status.
• Develop a risk-adapted treatment plan for patients with smoldering MM, considering the roles of observation and active treatment.
• Use cytogenetic profile and other patient- and disease-related factors to individualize the use of induction, consolidation and maintenance therapeutic approaches for patients with MM in the post-transplant and nontransplant settings.
• Consider published research data and other clinical factors in the best-practice selection, sequencing or combination of available therapeutic agents in the nonresearch care of patients with R/R MM.
• Compare and contrast the mechanisms of action, efficacy and safety of approved and investigational immunotherapeutic approaches (eg, checkpoint inhibitors, chimeric antigen receptor-directed T-cell therapy) for HL, non-Hodgkin lymphoma (NHL), CLL and MM to determine the current and potential utility of each approach in clinical practice.
• Design and implement a plan of care to recognize and manage side effects and toxicities associated with existing and recently approved systemic therapies for HL, NHL, CLL and MM to support quality of life and continuation of treatment.
• Assess the ongoing clinical trials evaluating other novel approaches for HL, NHL, CLL and MM, and obtain consent from appropriate patients for study participation.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
CME credit is no longer available for this issue

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
CME credit is no longer available for this issue

HOW TO USE THIS CME ACTIVITY
This CME activity consists of an audio component.
CME credit is no longer available for this issue

This CME activity consists of a video component.
CME credit is no longer available for this issue

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Noopur Raje, MD
Director, Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Consulting Agreements: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, Janssen Biotech Inc, Merck, Takeda Oncology; Contracted Research: AstraZeneca Pharmaceuticals LP.

Sonali M Smith, MD
Elwood V Jensen Professor of Medicine
Director, Lymphoma Program
The University of Chicago
Chicago, Illinois

Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Genentech, Gilead Sciences Inc, Kite Pharma Inc, Nordic Nanovector, Pharmacyclics LLC, an AbbVie Company, Portola Pharmaceuticals Inc, Seattle Genetics, TG Therapeutics Inc; Contracted Research: Celgene Corporation, Forty Seven Inc, Genentech, Pharmacyclics LLC, an AbbVie Company, Portola Pharmaceuticals Inc, Roche Laboratories Inc; Other Remunerated Activities: Educational lecture — Genentech; Medical science liaison, commercial teams — Kite Pharma Inc.

EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech, Genmab, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from AbbVie Inc, Adaptive Biotechnologies, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Genentech, Oncopeptides and Seattle Genetics.

Hardware/Software Requirements:
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
Adobe Flash Player 27 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

Release date: July 2019
Expiration date: July 2020